EUCTR2006-001663-33-CZ进行中（未招募）1 期
A randomised clinical trial of mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA associated vasculitis - MYCYC
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion (requires all)
- •i)New diagnosis of AASV (WG or MPA) (within the previous six months)
- •ii)Active disease (defined by at least one major or three minor BVAS 2003 items, see appendix 1)
- •iii)ANCA positivity (c-ANCA and PR3-ANCA or p-ANCA and MPO-ANCA) or histology confirming active vasculitis from any organ (see appendix )
- •iv)Written informed consent
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •i)Previous treatment with:
- •(1)MMF: more than two weeks ever.
- •(2)Cyclophosphamide: more than two weeks daily oral or more than 1 pulse of IV CYC (15mg/kg)
- •(3)Rituximab or high dose intravenous immunoglobulin within the last twelve months
- •ii)Active infection (including hepatitis B, C, HIV and tuberculosis).
- •iii)Known hypersensitivity to MMF, AZA or CYC.
- •iv)Cancer or an individual history of cancer (other than resected basal cell skin carcinoma).
- •v)Females who are pregnant, breast feeding, or at risk of pregnancy and not using a medically acceptable form of contraception.
- •vi)Any condition judged by the investigator that would cause the study to be detrimental to the patient.
- •vii)Any other multi-system autoimmune disease including Churg Strauss angiitis, SLE, anti GBM disease and cryoglobulinaemia.
研究者
相似试验
进行中（未招募）
1 期
A randomised clinical trial of mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA associated vasculitis - MYCYCAnti neutrophil cytoplasmic antibody (ANCA) associated vasculitisEUCTR2006-001663-33-DECambridge University Hospitals NHS Foundation Trust140
进行中（未招募）
1 期
A randomised clinical trial of mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA associated vasculitis - MYCYCAnti neutrophil cytoplasmic antibody (ANCA) associated vasculitis. Wegener´s granulomatosis (WG) and microscopic polyangiitis (MPA) are primary systemic vasculitides associated with ANCAEUCTR2006-001663-33-SECambridge University Hospitals NHS Foundation Trust140
进行中（未招募）
1 期
A randomised clinical trial of mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA associated vasculitis. - MYCYCPatient ayant une vascularite associée aux ANCAMedDRA version: 8.1Level: PTClassification code 10047115Term: VasculitisEUCTR2006-001663-33-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)140
进行中（未招募）
1 期
A randomised clinical trial of mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA associated vasculitis - MYCYCEUCTR2006-001663-33-GBCambridge University Hospitals NHS Foundation Trust140
进行中（未招募）
不适用
A randomised clinical trial of mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA associated vasculitis - MYCYCEUCTR2006-001663-33-ITVasculitis and Lupus Clinic140